Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-236.93M | $-1.45 |
| 2024 | $0.00 | $-243.79M | $-1.53 |
| 2023 | $0.00 | $-235.93M | $-1.49 |
| 2022 | $0.00 | $-130.90M | $-0.86 |
| 2021 | $0.00 | $-237.31M | $-1.56 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.22 per share
Typical surprise +4.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.23 vs $-0.24beat
- Thu, May 7$-0.30 vs $-0.32beat
- Mon, Mar 16$-0.35 vs $-0.34miss
- Thu, Nov 6$-0.35 vs $-0.34miss
- Wed, Aug 6$-0.33 vs $-0.38beat
- Mon, May 12$-0.42 vs $-0.40miss
Estimates and results for NMRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NMRAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
View source ↗